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RESUMEN
Se describe una síntesis eficiente de cetenaiminas en un 
solo recipiente usando un intermedio reactivo 1:1 genera-
do por la adición de isocianuros de alquilo a acetilenodi-
carboxilato de dialquilo y 2-hidroxibencimidazol.
Palabras clave: Esteres acetilénicos; isocianuros de al-
quilo; 2-hidroxibencimidazol; cetenaiminas.
SUMMARY
An efficient one-pot synthesis of ketenimines using 1:1 re-
active intermediate generated by the addition of alkyl iso-
cyanides to dialkyl acetylenedicarboxylate and 2-hydroxy 
benzimidazole is described.
Keywords: Acetylenic esters; alkyl isocyanides;  2-hy-
droxy benzimidazole; ketenimines.
RESUM
Es descriu una síntesi eficient de cetenaimines en un únic 
recipient  fent servir un reactiu intermedi 1:1 produït per 
l’adició d’isocianurs d’alquil a acetilendicarboxilat de dial-
quil i 2-hidroxibenzimidazole.
Paraules clau: Èsters acetilènics; isocianurs d’alquil; 2-hi-
droxibenzimidazole; cetenaimines.
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INTRODUCCIÓN
Benzimidazoles and its derivatives are a class of heterocy-
clic compounds which are known to play extremely crucial 
roles in the structures and functions of a number of biolog-
ically important molecules. The incorporation of the benz-
imidazole nuclei is an important synthetic strategy in drug 
discovery [1]. Applications of several benzimidazole deriv-
atives are include antimicrobial, antihypertensive, antican-
cer antiulcer, antifungal, antihistamine activity, herbicides, 
and other veterinary applications as promising drugs in 
different therapeutic categories [2-9]. The benzimidazole 
core structure is found in a variety of commercial drugs 
such as Atacand, Nexium, Micardis, Protonix, and Vermox 
[10-12]. The benzimidazole moieties express a significant 
activity against several viruses such as HIV, herpes (HSV-
1), RNA influenza, human cytomegalovirus, selective an-
giotensin II inhibitors, and 5-HT3 antagonists [2-9]. Other 
applications of benzimidazoles include their use as organ-
ic ligands, fluorescent whitening agent dyes and functional 
materials [13-17]. In addition, benzimidazoles are very im-
portant intermediates in synthetic routes [2-9]. Therefore, 
the construction of these heterocycles has always been of 
great interest to organic and medicinal chemists and has 
consequently received much attention [18, 19].
Meanwhile ketenimines have also found widespread use as 
reactive starting materials for the formation of four-, five-, and 
six-membered heterocyclic ring systems [20-23]. There has 
been intense interest in their reactions, such as cycloaddition 
[24], nucleophilic [25, 26] and electrophilic addition [20]. 
Recently, we have described a convenient method for 
preparation of ketenimines, by threecomponent reaction 
of NH acids, dialkyl acetylene dicarboxylates and alkyl iso-
cyanide [27-29]. In continuation of our interest in the ap-
plication of isocyanides in MCRs [30, 31], we extend this 
methodology using 2-hydroxy benzimidazole. Thus, the 
reaction of alkyl isocyanides 1 and dialkyl acetylene dicar-
boxylates 3 in the presence of 2-hydroxybenzimidazole 2 
leads to functionalized ketenimines 4 (Scheme 1).
MATERIALS AND METHODS
Melting points were measured on an Electrothermal 9100 
apparatus. IR spectra were recorded on a Perkin Elmer 
Precisely-100 FTIR spectrometer for KBr pellets. 1H and 
13C NMR spectra were recorded on a Bruker DRX300 
Avance instrument with CDCl3 as the solvent at 300 and 
75 MHz with TMS as internal standard, respectively. The 
mass spectra were recorded on a Finnigan-Matt 8430 
mass spectrometer operating at an ionization potential of 
70 eV. Alkyl isocyanides, dialkyl acetylene dicaboxylates 
and 2-hydroxy benzimidazole were obtained from Fluka 
and were used without further purification.
Tetramethyl 3,3’-(2-oxo-1H-benzo[d]imidazole-1,3(2H)-
diyl)bis(2-((tert-butylimino)methylene)succinate) (4a). 
To a stirred solution of 2-hydroxy benzimidazole (0.26 g, 2 
mmol) and tert-butyl isocyanide (0.18 g, 2 mmol) in 10 ml 
of CH2Cl2, dimethyl acetylene dicarboxylate (DMAD) (0.28 
g, 2 mmol) was added dropwise and the reaction mixture 
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Fig. 2. Scheme 2
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for 24 h. The solvent was removed under reduced pres-
sure and oil products were purified by preparative TLC on 
silica gel (Merck silica gel DCFertigplatten 60/Kieselgur 
F254) 20×20 cm plates using n-hexane-EtOAc (2:1) as elu-
ent. Yield 970 mg (83%), white, powder, mp 151-152 °C. 
IR spectrum, ν, cm-1: 1667, 1731 (C=O), 2067 (–C=C=N). 
1H NMR spectrum (300 MHz, CDCl3), δ, ppm (J, Hz): 1.35 
(9H, s, 3-CH3); 1.36 (9H, s, 3-CH3); 3.68 (6H, s, 2-OCH3); 
3.72 (6H, s, 2-OCH3); 5.96 (1H, s, CH); 5.98 (1H, s, CH); 
7.06-7.08 (2H, m, 2-CHArom); 7.17-7.21 (2H, m, 2-CHArom). 
13C NMR spectrum, δ, ppm: 29.9 (2-(CH3)3); 51.7 (2-OCH3); 
52.3 (2-OCH3); 52.3 (CH);53.0 (CH); 61.1 (-C=C=N); 61.3 
(-C=C=N); 62.4 (2-CN); 109.3 (2-CHArom); 121.6 (2-CHArom); 
128.4 (2-CArom); 153.1 (C=O); 164.0 (2-CO2); 168.2 (2-CO2); 
169.8 (2-C=C=N). Mass spectrum (EI, 70 eV), m/z (Irel, %): 
584 [M]+ (14), 486 [M–C6H12N]
+ (19), 380 [M–C8H16NO5]
+ 
(57), 358 [M–C11H16NO4]
+ (100). Found, %: C 59.56; H 6.22; 
N 9.56. C29H36N4O9. Calculated, %: C 59.58; H 6.21; N 9.58.
Tetramethyl 3,3’-(2-oxo-1H-benzo[d]imidazole-1,3(2H)-di-
yl)bis(2-((cyclohexylimino)methylene)succinate) (4b). Was 
prepared similarly to compound 4a from 2-hydroxy benz-
imidazole (0.26 g, 2mmol), cyclohexyl isocyanide (0.20 g, 2 
mmol) and dimethyl acetylene dicarboxylate (DMAD) (0.28 g, 
2 mmol). Yield 966 mg (76%), white, powder, mp 152-154°C. 
IR spectrum, ν, cm-1: 1670, 1733 (C=O), 2071 (–C=C=N). 1H 
NMR spectrum (300 MHz, CDCl3), δ, ppm (J, Hz): 1.05-2.04 
(20H, m, 10-CH2); 3.68 (6H, s, 2-OCH3); 3.73 (3H, s, OCH3); 
3.80 (3H, s, OCH3); 3.71 (1H, m, CH); 3.77 (1H, m, CH); 5.96 
(1H, s, CH); 5.97 (1H, s, CH); 7.10-7.15 (2H, m, 2-CHArom); 7.17-
7.21 (2H, m, 2-CHArom). 
13C NMR spectrum, δ, ppm: 23.9 (CH2); 
24.1 (CH2); 24.6 (CH2); 24.8 (CH2); 25.4 (CH2); 25.7 (CH2); 29.7 
(CH2); 32.1 (CH2); 32.6 (CH2); 33.0 (CH2); 48.9 (2-OCH3); 51.6 
(OCH3); 52.4 (OCH3); 52.6 (CH); 52.9 (CH); 59.7 (2-C=C=N); 
60.7 (CHN); 60.8 (CHN); 108.7 (CHArom); 109.1 (CHArom); 121.6 
(CHArom); 122.0 (CHArom); 128.5 (CArom); 129.0 (CArom); 152.7 
(C=O); 163.4 (CO2); 164.0 (CO2); 168.0 (CO2); 168.3 (CO2); 
169.7 (2-C=C=N). Mass spectrum (EI, 70 eV), m/z (Irel, %): 
636 [M]+ (32), 512 [M–C8H14N]
+ (17), 406 [M–C10H18NO5]
+ (39), 
384 [M–C13H18NO4]
+ (100). Found, %: C 62.26; H 6.33; N 8.78. 
C33H40N4O9. Calculated, %: C 62.25; H 6.33; N 8.80.
Tetraethyl 3,3’-(2-oxo-1H-benzo[d]imidazole-1,3(2H)-diyl)
bis(2-((tert-butylimino)methylene)succinate) (4c). was pre-
pared similarly to compound 4a from 2-hydroxy benzimid-
azole (0.26 g, 2 mmol), tert-butyl isocyanide (0.18 g, 2 mmol) 
and diethyl acetylene dicarboxylate (DEAD) (0.34 g, 2 mmol). 
Yield 1.1 g (86%), white, powder, mp 158-59 °C. IR spec-
trum, ν, cm-1: 1665, 1721 (C=O), 2065 (–C=C=N).  1H NMR 
spectrum (300 MHz, CDCl3), δ, ppm (J, Hz): 1.18-1.25 (12H, 
m, 4-CH3); 1.35 (9H, s, 3-CH3); 1.36 (9H, s, 3-CH3); 4.05-4.29 
(8H, m, 4-OCH2); 5.95 (1H, s, CH); 5.97 (1H, s, CH); 7.05-7.08 
(2H, m, 2-CHArom); 7.19-7.22 (2H, m, 2-CHArom). 
13C NMR spec-
trum, δ, ppm: 14.0 (2-CH3); 14.3 (2-CH3); 30.0 (2-(CH3)3); 52.2 
(CH); 52.3 (CH); 60.3 (2-C=C=N); 61.7 (OCH2); 61.8 (OCH2); 
62.0 (2-CN); 62.2 (OCH2); 62.3 (OCH2); 109.4 (2-CHArom); 121.4 
(2-CHArom); 128.4 (CArom); 128.5 (CArom); 151.9 (C=O); 167.7 (2-
CO2); 169.2 (2-CO2); 169.3 (2-C=C=N). Mass spectrum (EI, 
70 eV), m/z (Irel, %): 640 [M]+ (25), 542 [M–C6H12N]
+ (21), 406 
[M–C10H20NO5]
+ (54), 386 [M–C13H20NO4]
+ (100). Found, %: C 
61.88; H 6.90; N 8.73. C33H44N4O9. Calculated, %: C 61.86; H 
6.92; N 8.74.
Tetraethyl 3,3’-(2-oxo-1H-benzo[d]imidazole-1,3(2H)-diyl)
bis(2-((cyclohexylimino)methylene)succinate) (4d). was 
prepared similarly to compound 4a from 2-hydroxy benzimid-
azole (0.26 g, 2 mmol), cyclohexyl isocyanide (0.20 g, 2 mmol) 
and diethyl acetylene dicarboxylate (DEAD) (0.34 g, 2 mmol). 
Yield 1.07 g (78%), light-yellow, powder, mp 157-159°C. IR 
spectrum, ν, cm-1: 1668, 1727 (C=O), 2074 (–C=C=N).  1H 
NMR spectrum (300 MHz, CDCl3), δ, ppm (J, Hz): 1.10-1.84 
(20H, m, 10-CH2); 1.16-1.37 (12H, m, 4-CH3); 3.41 (
1H, m, 
CH); 3.69 (1H, m, CH); 4.00-4.30 (8H, m, 4-OCH2); 5.48 (1H, 
s, CH); 5.56 (1H, s, CH); 7.01-7.23 (4H, m, 4-CHArom). 
13C NMR 
spectrum, δ, ppm: 13.9 (2-CH3); 14.0 (2-CH3); 23.9 (CH2); 
24.6 (CH2); 24.8 (CH2); 25.3 (CH2); 25.4 (CH2); 25.7 (CH2); 
29.7 (CH2); 31.9 (CH2); 32.1(CH2); 32.6 (CH2); 48.8 (CH); 49.0 
(CH); 54.4 (C=C=N); 54.6 (C=C=N); 61.8 (OCH2); 61.9 (OCH2); 
62.1 (CHN); 62.1 (CHN); 62.3 (OCH2); 62.5 (OCH2); 108.9 (2- 
CHArom); 122.0 (CHArom); 122.2 (CHArom); 128.9 (2-CArom); 152.4 
(C=O); 163.4 (CO2); 166.7 (CO2); 167.4 (CO2); 167.6 (CO2); 
168.6 (2-C=C=N). Mass spectrum (EI, 70 eV), m/z (Irel, %): 
692 [M]+ (10), 568 [M–C8H14N]+ (11), 432 [M–C12H22NO5]
+ (46), 
412 [M–C15H22NO4]
+ (100). Found, %: C 64.17; H 6.97; N 8.08. 
C37H48N4O9. Calculated, %: C 64.15; H 6.98; N 8.09.
Tetra-tert-butyl 3,3’-(2-oxo-1H-benzo[d]imidazole-
1,3(2H)-diyl)bis(2-((cyclohexylimino)methylene)succinate) 
(4e). was prepared similarly to compound 4a from 2-hydroxy 
benzimidazole (0.26 g, 2 mmol), cyclohexyl isocyanide (0.20 
g, 2 mmol) and ditert-butyl acetylene dicarboxylate (DTAD) 
(0.46 g, 2 mmol). Yield 1.41 g (88%), white, powder, mp 169-
170 °C. IR spectrum, ν, cm-1: 1662 (C=O), 2070 (–C=C=N).  1H 
NMR spectrum (300 MHz, CDCl3), δ, ppm (J, Hz): 1.11-1.94 
(20H, m, 10-CH2); 1.38 (9H, s, 3-CH3); 1.40 (9H, s, 3-CH3); 
1.42 (9H, s, 3-CH3); 1.50 (9H, s, 3-CH3); 3.42 (1H, m, CH); 3.80 
(1H, m, CH); 5.81 (1H, s, CH); 5.86 (1H, s, CH); 7.00-7.06 (2H, 
m, 2-CHArom); 7.12-7.18 (2H, m, 2-CHArom). 
13C NMR spectrum, 
δ, ppm: 23.8 (CH2); 24.7 (CH2); 25.3 (CH2); 25.5 (CH2); 27.3 
(CH2); 27.4 (CH2); 27.7 (CH2); 27.9 (2-(CH3)3); 28.4 (2-(CH3)3); 
29.7 (CH2); 32.7 (CH2); 33.0 (CH2); 48.4 (CH); 48.6 (CH); 53.0 
(2- C=C=N); 60.5 (CHN); 62.1 (CHN); 80.2 (O–C(CH3)3); 80.3 
(O–C(CH3)3); 82.5 (O–C(CH3)3); 82.7 (O–C(CH3)3); 108.7 (CHA-
rom); 109.3 (CHArom); 121.4 (2-CHArom); 121.5 (CArom); 128.6 (CAr-
om); 153.3 (C=O); 166.8 (4-CO2); 168.3 (2-C=C=N). Mass spec-
trum (EI, 70 eV), m/z (Irel, %): 804 [M]+ (28), 680 [M–C8H14N]
+ 
(23), 490 [M–C16H30NO5]
+ (59), 468 [M–C19H30NO4]
+ (100). 
Found, %: C 67.14; H 8.03; N 6.95. C45H64N4O9. Calculated, 
%: C 67.14; H 8.01; N 6.96.
Tetramethyl 3,3’-(2-oxo-1H-benzo[d]imidazole-1,3(2H)-
diyl)bis(2 -(((2,4,4-trimethylpentan-2-yl)imino)methylene)
succinate) (4f). was prepared similarly to compound 4a from 
2-hydroxy benzimidazole (0.26 g, 2 mmol), 1,1,3,3-tetrameth-
yl-butyl isocyanide (0.28 g, 2 mmol) and dimethyl acetylene 
dicarboxylate (DMAD) (0.28 g, 2 mmol). Yield 1.1 g (79%), 
white, powder, mp 160-162°C. IR spectrum, ν, cm-1: 1652 
(C=O), 2073 (–C=C=N).  1H NMR spectrum (300 MHz, CDCl3), 
δ, ppm (J, Hz): 1.01 (18H, s, 6-CH3); 1.40 (6H, s, 2-CH3); 1.42 
(6H, s, 2-CH3); 1.57 (2H, s, CH2); 1.59 (2H, s, CH2); 3.65 (6H, 
s, 2-OCH3); 3.72 (6H, s, 2-OCH3); 5.96 (1H, s, CH); 5.99 (1H, 
s, CH); 7.05-7.08 (2H, m, 2-CHArom); 7.18-7.23 (2H, m, 2-CHA-
rom). 
13C NMR spectrum, δ, ppm: 30.7 (CH3); 30.8 (CH3); 30.9 
(CH3); 31.0 (2-(CH3)3); 31.4 (CH3); 31.6 (2-C); 51.4 (2-CH2); 
52.2 (OCH3); 52.3 (OCH3); 52.9 (2-OCH3); 54.4 (2-CH); 60.5 
(C=C=N); 60.6 (C=C=N); 65.1 (C-N); 65.2 (C-N); 109.4(CHArom); 
109.5 (CHArom); 121.5 (2-CHArom); 128.3 (CArom); 128.4 (CArom); 
152.1 (C=O); 162.1 (2-CO2); 168.3 (2-CO2); 170.0 (2-C=C=N). 
Mass spectrum (EI, 70 eV), m/z (Irel, %): 696 [M]+ (12), 542 [M–
C10H20N]
+ (15), 432 [M–C12H24NO5]
+ (38), 414 [M–C15H24NO4]
+ 
(100). Found, %: C 63.80; H 7.51; N 8.04. C37H52N4O9. Calcu-
lated, %: C 63.77; H 7.52; N 8.04.
Tetraethyl 3,3’-(2-oxo-1H-benzo[d]imidazole-1,3(2H)-diyl)
bis(2-(((2,4,4-trimethylpentan-2-yl)imino)methylene)suc-
cinate) (4g). was prepared similarly to compound 4a from 
2-hydroxy benzimidazole (0.26 g, 2 mmol), 1,1,3,3-tetrameth-
yl-butyl isocyanide (0.28 g, 2 mmol) and diethyl acetylene 
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dicarboxylate (DEAD) (0.34 g, 2 mmol). Yield 1.02 g (68%), 
white, powder, mp 164-166°C. IR spectrum, ν, cm-1: 1654 
(C=O), 2074 (–C=C=N).  1H NMR spectrum (300 MHz, CDCl3), 
δ, ppm (J, Hz): 1.01 (9H, s, (CH3)3); 1.03 (9H, s, (CH3)3); 
1.09-1.46 (12H, m, 4CH3); 1.41 (6H, s, 2-CH3); 1.48 (6H, s, 
2-CH3); 1.58 (2H, s, CH2); 1.67 (2H, s, CH2); 4.08-4.53 (8H, 
m,4-OCH2); 5.95 (1H, s, CH); 5.98 (1H, s, CH);7.05-7.23 (4H, 
m, 4-CHArom). 
13C NMR spectrum, δ, ppm: 14.0 (2-CH3); 14.4 
(2-CH3); 30.7 (CH3); 30.9 (CH3); 31.1 (2-(CH3)3); 31.4 (CH3); 31.6 
(C); 31.7 (C);  32.0 (CH3); 52.4 (2-CH2); 54.4 (CH); 58.5 (CH); 
59.6 (2-C=C=N); 60.2 (2-OCH2); 62.0 (2-OCH2);  65.0 (C-N); 
65.1 (C-N); 109.4(CHArom); 109.5 (CHArom); 121.3 (2-CHArom); 
128.0 (CArom); 128.5 (CArom); 152.5 (C=O); 162.9 (CO2); 163.1 
(CO2); 167.8 (2-CO2); 169.5 (C=C=N) ; 169.6 (C=C=N). Mass 
spectrum (EI, 70 eV), m/z (Irel, %): 752 [M]+ (24), 600 [M –
C10H20N]
+ (28), 462 [M–C14H28NO5]
+ (53), 442 [M–C17H28NO4]
+ 
(100). Found, % C 65.42; H 8.02; N 7.40. C41H60N4O9. Calcu-
lated, %: C 65.40; H 8.03; N 7.44.
RESULTS AND DISCUSSION
The reaction proceeded spontaneously at room tempera-
ture in dichloromethane, and was completed within a few 
hours. The structure of 4 was determined on the basis of 
its elemental analyses, mass spectrum (MS), 1H and 13C 
NMR and IR spectroscopic data.
The 1H NMR spectrum of 4a exhibited six signals for tert-
butyl (δ = 1.35 and 1.36 ppm), metoxy (δ = 3.68 and 3.72 
ppm), and methine (5.96 and 5.98 ppm) protons. The ar-
omatic moiety appeared as a multiplet at 7.06–7.08 and 
7.17–7.21 ppm. The 13C NMR spectrum of compound 4a 
showed distinct 15 resonances in agreement with the pro-
posed structure. Partial assignments of these resonances 
are given in the Experimental. The 1H NMR spectra of 
compounds 4b–4g are similar to that of compound 4a, 
except for the signals of the alkyl isocyanides and ester 
moiety. The structural assignments of compounds 4a–4g 
made on the basis of their NMR spectra were supported 
by their IR spectra. Of special interest is the strong keteni-
mine absorption band at about 2067 cm-1.
 It is conceivable that the reaction involves the initial for-
mation of the 1:1 zwitterionic intermediate 5 between the 
isocyanide and dialkyl acetylenedicarboxylates. The pro-
tonation of compound 5 by the NH-acidic 2 leads to inter-
mediate 6. Subsequent attack of the resulting nucleophile 
7 on the positively charged ion 6 ketenimines. The same 
path for another NH was occurred, to product ketenimines 
4. Similar mechanistic scheme can be considered for for-
mation of compounds 4a–4g (Scheme 2).
CONCLUSION
In conclusion, we have found a simple and efficient meth-
od for the preparation of highly functionalized ketenimines. 
The present method carries the advantage that not only 
the reaction is performed under neutral conditions, but 
also the starting materials and reagents can be mixed 
without any activation or modification.
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